Dr. Howard Lazarus is Altavant’s Chief Medical Officer. He was most recently a Medical Expert/Executive Director in Clinical Development and Medical Affairs at Boehringer Ingelheim Pharmaceuticals where he was a member of the leadership team focusing on interstitial lung diseases such as idiopathic pulmonary fibrosis (IPF). Earlier, at Gilead Sciences, Dr. Lazarus served as Director, Medical Affairs in the company’s cardiopulmonary division. In this role, he also contributed to clinical research and worked closely with cross functional colleagues in marketing and commercial strategy formulating communication plans for Gilead’s approved and pipeline programs for pulmonary arterial hypertension (PAH) and IPF. Between 1997 and 2012, Dr. Lazarus practiced as a pulmonary and critical care physician at several health facilities, most recently at Oregon Pulmonary Associates in Portland. In that role, he and a team of experts diagnosed and treated patients with complex pulmonary vascular and interstitial diseases such as PAH and IPF, many of whom were referred to their sub-specialty center from area hospitals. Dr. Lazarus earned both a Bachelor of Science in Biochemistry and his MD from McGill University in Montreal. His residency in Internal Medicine was at Boston University Medical Center and he completed a fellowship in Pulmonary & Critical Care Medicine at the University of California, San Diego. He is a Fellow of the American College of Chest Physicians and a member of the American Thoracic and European Respiratory Societies.